

CRESANTO GLOBAL LIMITED

(Formerly known as Raymed Labs Limited)

CIN: L22203UP1992PLC014240

Reg.off.- C- 273 , C block , sector 63, Gautam Buddha Nagar, Noida, Uttar Pradesh, India, 201301, Website- www.raymedlab.com

Email- raymedlabs@rediffmail.com, Phone no. 7738669898

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai- 400001

Scrip code- 531207

Subject: Outcome of Board Meeting

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., 05th November, 2025, has inter alia considered and approved the following matters:

1. Un-Audited Financial Results of the Company for the second quarter and half year ended 30th September, 2025, together with all the Limited Review report for the second quarter and half year ended 30th September, 2025 prepared in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is attached herewith.

The un-audited financial results for the second quarter and half year ended 30th September, 2025 along with Limited Review Report will be made available on the Company's website.

The meeting commenced at 12:30 p.m. and concluded at 02:10 p.m.

Kindly take the same on record.

For Cresanto Global Limited

(Formerly known as Raymed Labs Limited)

(Prashant Nathmal Bajaj)

Managing Director

DIN: 06634046

Date: 05th November, 2025

Place: Mumbai

Limited Review Report on the Unaudited Quarterly and year-to-date Standalone Financial Results of Cresanto Global Limited (Formerly known as Raymed Labs Limited) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
Cresanto Global Limited

1. We have reviewed the accompanying statement of unaudited standalone Financial Results of Cresanto Global Limited (Formerly known as Raymed Labs Limited) ("the Company") for the quarter ended 30th September 2025 ("the statement"). This statement is being submitted to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (Listing Regulations)
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K T P S & Co.
Chartered Accountants
Firm's Registration No. 134942W


CA Anurag Khandella
Partner
Mem. No. 172909
UDIN: 25172909BMIGKA4388



Place: Mumbai
Date: 05/11/2025

CRESANTO GLOBAL LIMITED (formerly known as Raymed Labs Limited)

UNAUDITED BALANCE SHEET AS AT SEPTEMBER 30, 2025

(INR in Lakhs)

Particulars	Note No.	As at Sept 30, 2025	As at Sept 30, 2024	As at March 31, 2025
I ASSETS				
1. Non Current Assets				
(a) Property, Plant and Equipment	5	-	14.28	-
(b) Capital Work-In-Progress		-	-	-
(c) Investment Property		-	-	-
(d) Intangible Assets		-	-	-
(e) Intangible Assets Under Development		-	-	-
(f) Financial Assets		-	-	-
(g) Income Tax Assets (Net)	6	-	-	-
(h) Other Non Current Assets		-	-	-
		-	14.28	-
2. Current Assets				
(a) Inventories	7	-	-	-
(b) Financial Assets				
(i) Investments		-	-	-
(ii) Trade Receivables	8	6.36	-	-
(iii) Cash and Cash Equivalents	9	0.83	100.05	0.01
(iv) Other Bank Balances other than (iii) above		-	-	-
(v) Loans	10	-	0.45	-
(vi) Others	11	0.12	-	-
(c) Current Tax Assets	12	3.11	-	3.11
		10.42	100.50	3.12
Total Assets		10.42	114.79	3.12
II EQUITY AND LIABILITIES				
Equity				
(a) Equity Share Capital	13	427.35	427.35	427.35
(b) Other Equity	14	(696.19)	(671.52)	(686.14)
		(268.84)	(244.17)	(258.79)
LIABILITIES				
1. Non Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	15	247.13	346.16	237.12
(b) Provisions		-	-	-
(c) Deferred Tax Liabilities (Net)	16	-	-	-
		247.13	346.16	237.12
2. Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings		-	-	-
(ii) Trade Payable	17	-	-	-
(iii) Other Financial Liabilities	18	32.15	5.00	23.14
(b) Other Current Liabilities	19	-	7.81	1.67
(c) Provisions	20	-	-	-
(d) Current Tax Liabilities (Net)	21	-	-	-
		32.15	12.81	24.81
Total Equity and Liabilities		10.42	114.79	3.12
Summary of Significant Accounting Policies	2-4			

The notes referred to above are an integral part of the financial statements

For and on behalf of the Board of Directors

Prashant Nathmal Bajaj
 Managing Director & CFO
 DIN- 06634046
 Place: Mumbai
 Dated : 05.11.2025

CRESANTO GLOBAL LIMITED (formerly known as Raymed Labs Limited)

STATEMENT OF UNAUDITED PROFIT AND LOSS FOR THE PERIOD ENDED SEPTEMBER 30, 2025

(INR in Lakhs)

Particulars	Note No.	For The qtr ended September 30, 2025	For The qtr ended June 30, 2025	For The qtr ended September 30, 2024	For the half year ended September 30, 2025	For the half year ended September 30, 2024	For the Year ended March 31, 2025
I Revenue							
Revenue from Operations	22	5.39	-	-	5.39	-	-
Other Income	23	-	-	-	-	-	52.59
Total Income		5.39	-	-	5.39	-	52.59
II Expenses							
Purchases of Stock in Trade		5.22	-	-	5.22	-	-
Change in Inventories of Finished Goods/Work-in-progress/ Stock in Trade	24	-	-	-	-	-	-
Employee Benefits Expenses	25	0.60	3.60	0.80	4.20	1.70	21.45
Finance Costs	26	-	0.01	0.00	0.01	0.00	11.49
Depreciation and Amortization Expenses	27	-	-	0.11	-	0.29	0.44
Other Expenses	28	0.42	5.60	0.74	6.02	1.43	37.26
Total Expenses		6.24	9.21	1.66	15.45	3.43	70.64
III Profit before tax (I- II)		(0.85)	(9.21)	(1.66)	(10.06)	(3.43)	(18.05)
IV Less: Tax Expense:							
Current Tax		-	-	-	-	-	-
MAT Credit Entitlement		-	-	-	-	-	-
Deferred Tax		-	-	-	-	-	-
Total Tax Expense		-	-	-	-	-	-
V Profit for the Year (III-IV)		(0.85)	(9.21)	(1.66)	(10.06)	(3.43)	(18.05)
VI Other Comprehensive Income							
Items that will not be reclassified to profit or loss							
Re-measurement gains/ (losses) on defined benefit obligations		-	-	-	-	-	-
Tax Effect on above		-	-	-	-	-	-
Other Comprehensive Income for the year, net of tax		-	-	-	-	-	-
VII Total Comprehensive Income for the year (V+VI) (Comprising Profit and Other Comprehensive Income for the year)		(0.85)	(9.21)	(1.66)	(10.06)	(3.43)	(18.05)
VIII Earnings Per Equity Share (Face Value INR 10 Per Share):	29						
Basic and Diluted (INR)		(0.02)	(0.22)	(0.04)	(0.24)	(0.08)	(0.42)
Summary of Significant Accounting Policies	2-4						

The notes referred to above are an integral part of the financial statements

For and on behalf of the Board of Directors

Prashant Nathmal Bajaj
 Managing Director & CFO
 DIN- 06634046
 Place: Mumbai
 Dated : 05.11.2025

CRESANTO GLOBAL LIMITED (formerly known as Raymed Labs Limited)
Unaudited Cash Flow Statement for the period ended 30.09.2025

Particulars	For the Year ended Sept 30, 2025	For the Year ended Sept 30, 2024	For the Year ended March 31, 2025
A. Cash Flow from Operating Activities			
Net Profit Before Tax	(10.06)	(3.43)	(18.05)
Adjustments:			
Depreciation and Amortization of Property, Plant and Equipment	-	0.29	0.44
Loss on Sale of property, plant and equipment (net)	-	-	-
Profit on Sale of Property, Plant and Equipment	-	-	(50.82)
Fees on Guarantee given on behalf of the Subsidiary Company	-	-	-
Finance Costs (Including Fair Value Change in Financial Instruments)	0.01	0.00	11.49
Operating cash flows before working capital changes	(10.05)	(3.13)	(56.94)
Adjustments for Changes in Working Capital			
Decrease/ (Increase) in Inventories	-	-	-
Decrease/ (Increase) in Trade receivables	(6.36)	-	-
Decrease/ (Increase) in Current Loans	-	-	0.45
Decrease/ (Increase) in Non-Current Financial Assets - Others	-	-	-
Decrease/ (Increase) in Other Current Financial Assets	(0.12)	-	-
Decrease/ (Increase) in Other Current Assets	-	-	(3.11)
Increase/ (Decrease) in Trade Payables	-	-	-
Increase/ (Decrease) in Current Financial Liabilities - Other	9.01	-	10.47
Increase/ (Decrease) in Other Current Liabilities	(1.67)	0.15	1.67
Increase/ (Decrease) in Non-Current Provisions	-	-	-
Increase/ (Decrease) in Current Provisions	-	-	-
Cash generated from operations	(9.19)	(2.98)	(47.46)
Income taxes paid	-	-	-
Net cash flow from operating activities	(9.19)	(2.98)	(47.46)
Less : Finance cost paid	(0.01)	(0.00)	-
Net cash flow(Used in) from operating activities (A)	(9.20)	(2.99)	(47.46)
B. Cash Flow from Investing Activities			
Purchase or construction of property, plant and equipment (including capital work-in-progress and capital advances)	-	-	-
Proceeds from/ (Investment in) fixed deposits (net)	-	-	-
Proceeds from/ (Investment in) Other Bank Balances	-	-	-
Proceeds from sale of property, plant and equipment	-	-	64.96
Purchase or construction of Investment Properties	-	-	-
Loan taken / (Repayment) of Loan	10.01	102.99	(6.05)
Interest Received	-	-	-
Dividend Received	-	-	-
Net cash flow from/ (used in) investing activities (B)	10.01	102.99	58.91
C. Cash Flow from Financing Activities			
Increase/(Decrease) Non-Current Financial Liabilities - Borrowings	-	-	-
Interest Paid	-	-	(11.49)
Proceeds from public issue of shares	-	-	-
Proceeds from securities premium (net of QIP expenses)	-	-	-
Net cash flow from financing activities ©	-	-	(11.49)
Net cash Increase/(decrease) in cash and cash equivalents (A+B+C)	0.82	100.00	(0.04)
Cash and cash equivalents at the beginning of the year (Refer Note 9)	0.01	0.05	0.05
Cash and cash equivalents at the end of the year (Refer Note 9)	0.83	100.05	0.01
Net cash Increase/(decrease) in cash and cash equivalent	0.82	100.00	(0.04)

The notes referred to above are an integral part of the financial statements.
As per our report of even date

For and on behalf of the Board of Directors

Prashant Nathmal Bajaj
Managing Director & CFO
DIN- 06634046
Place: Mumbai
Dated : 05.11.2025